Biopharmaceuticals are used widely for the treatment of cancer, chronic viral hepatitis, inflammatory, and autoimmune diseases. Biopharmaceuticals such as interferons are well tolerated for the most part with the most common adverse events observed being 'flu-like' symptoms that resolve rapidly after initial treatment. Prolonged treatment is associated, however, with more serious adverse events including leucopenia, thrombocytopenia, and neuropsychiatric effects, which may necessitate dose reduction or even cessation of treatment in some patients. Recombinant growth factors, such as erythropoietin (EPO), granulocyte colony-stimulating factor, or granulocyte macrophage colony-stimulating factor, are for the most part well tolerated, although severe complications have been reported in patients with cancer or chronic kidney disease treated with EPO. Similarly, treatment of patients with cancer with high doses of interleukin-2 is associated with significant toxicity. Treatment of chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, with antitumor necrosis factor-alpha monoclonal antibodies is associated with an increased risk of granulomatous infections and, in particular, tuberculosis. The monoclonal antibody, natalizumab, that targets alpha4 integrins is effective in the treatment of multiple sclerosis but is associated with the activation of JC virus and development of progressive multifocal leukoencephalopathy. Repeated administration of recombinant proteins can cause a break in immune tolerance in some patients resulting in the production of a polyclonal antibody response that can adversely affect pharmacokinetics and clinical response. In addition, neutralizing antibodies that cross react with nonredundant essential proteins such as EPO can cause severe autoimmune reactions.
Introduction
Biopharmaceuticals are an important class of pharmaceuticals that are used widely in clinical medicine. Among the most widely used biopharmaceuticals are monoclonal antibodies used in the therapy of cancer or inflammatory and autoimmune diseases, and recombinant analogues of growth factors such as insulin or erythropoietin (EPO), or cytokines such as type I interferons (IFNs) or interleukin 2 (IL-2). This is reflected by sales of some US$92 billion in 2009 (Table 1) [La Merie Business Intelligence, 2010].
The safety and efficacy of recombinant biopharmaceuticals can be severely impaired, however, by the ability of patients to tolerate the drug. Type I IFNs and IL-2 were among the first biopharmaceuticals to be licensed for use in man and their toxicity profile is well characterized. A consideration of the clinical experience with the use of these molecules as well as with the use of some of the first monoclonal antibodies to be used extensively in the clinic, serves to illustrate the types of adverse events that can be encountered with biopharmaceuticals.
Immunogenicity can also limit the use of biopharmaceuticals, particularly for the treatment of chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA) or multiple sclerosis (MS). Although it is widely accepted that injection of foreign proteins can elicit an immune reaction leading to the production of antidrug antibodies (ADAs), it is becoming increasingly apparent that repeated injection of recombinant homologues of authentic human proteins, such as IFNs or EPO, especially when aggregated or partially denatured, can result in a break in immune tolerance to self-antigens leading to the production of an ADA response.
ADAs can adversely affect the pharmacokinetics, bioavailability, and efficacy of biopharmaceuticals and in some cases may neutralize the activity of the drug. ADAs can also cause immune complex disease, allergic reactions and, in some cases, severe autoimmune reactions. Assessment of immunogenicity is therefore an important component of drug safety evaluation.
Adverse events associated with the administration of biopharmaceuticals In the following sections the type of adverse events that have been observed in the clinical use of bipharmaceuticals will be reviewed by reference to the use of type I IFNs (IFNa2 and IFNb-1), IL-2, EPO, and the monoclonal antibodies, rituximab, natalizumab, daclizumab, and alemtuzumab. Emphasis will be given to an understanding of the emerging pattern of common adverse events observed with different classes of drug products.
Type I IFNs
Type I IFNs play a determining role in the innate immune response and in the establishment of the subsequent adaptive immune response and resistance to virus infection [O'Neill and Bowie, 2010; Content, 2009] . Type I IFNs bind to a common high-affinity cell-surface receptor composed of two transmembrane polypeptide chains, IFNAR1 and IFNAR2. IFN binding results in the phosphorylation and activation of two Janus kinases, Tyk2 and Jak1, and activation of the latent cytoplasmic signal transducers and activators of transcription (STAT) 1 and 2, and the formation of a transcription complex in association with IFN regulatory factor 9 (IRF9). Translocation of this complex to the nucleus results in the transcriptional activation of a specific set of genes that encode the effector proteins responsible for mediating the biological activities of the type I IFNs [O'Neill and Bowie, 2010; Content, 2009] . Recombinant IFNa2 and more recently pegylated IFNa2a and pegylated IFNa2b, have found wide application for the treatment of chronic viral hepatitis [McHutchison et al. 2009 ] and some neoplastic diseases [Kiladjian et al. 2008] , while IFNb-1 is used extensively as first-line therapy for the treatment of RRMS [Farrell and Giovannoni, 2010] .
Type I IFNs are for the most part well tolerated although mild adverse events, including acute flu-like symptoms, are observed in most patients. More serious chronic side effects, such as myelosuppression, induction or exacerbation of underlying autoimmune disease, and neuropsychiatric effects, are also observed in some patients. Adverse events are usually dose-dependent and a function of the particular IFN used, the disease state, and the genetic makeup of the individual being treated. The majority of patients treated with standard therapeutic doses of native or pegylated IFNa2 or native IFNb-1 exhibit flu-like symptoms, including fever, headache, chills, and myalgia, within 13 h of the initiation of IFN treatment. These symptoms decrease in intensity over time, and are believed to be due to both the release of the inflammatory cytokines IL-1, IL-6, and tumor necrosis factor alfa (TNFa), and induction of prostaglandin-E 2 in the hypothalamus [Dinarello et al. 1984] .
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IFNa2b, and can be sufficiently severe to necessitate dose reduction or even discontinuation of treatment [Sleijfer et al. 2005] . Anemia and thrombocytopenia is also observed in approximately 6% of patients with chronic hepatitis C treated with PEG-IFNa2a or PEG-IFNa2b and often leads to dose reduction or discontinuation of treatment [Harris et al. 2001] . Hematological adverse events can be particularly severe in patients co-infected with hepatitis C virus and human immunodeficiency virus and treated with pegylated IFNa2 and ribavirin [Mira et al. 2007; Simin et al. 2007 ]. An association between polymorphisms in the genes encoding IFNAR1 and STAT2, and IFN-induced neutropenia has recently been reported in certain populations with chronic hepatitis C treated with type I IFN [Wada et al. 2009 ]. Similarly, IFN-induced thrombocytopenia was found to be associated with a polymorphism in the gene encoding IRF7 [Wada et al. 2009 ]. In contrast, these polymorphisms were not associated with a sustained virologic response to IFN therapy that was dependent upon independent factors including viral load, viral genotype, and the degree of liver fibrosis on initiation of IFN treatment.
Elevated levels of liver transaminases are also a common side effect observed during the first weeks of treatment of patients with IFNa. The effects are dose dependent and resolve rapidly on cessation of IFN therapy [Sleijfer et al. 2005 ].
Induction or exacerbation of pre-existing autoimmune disease is observed in some patients treated with type I IFNs Nordmark et al. 2009 ]. Recent genome-wide association studies have identified alleles associated with susceptibility to a number of autoimmune diseases some of which encode proteins involved in IFN induction or IFN signaling [Hellquist et al. 2009; Kyogoku et al. 2009; Miceli-Richard et al. 2009; Nordmark et al. 2009; Suarez-Gestal et al. 2009a , 2009b Cunninghame Graham et al. 2007; Miceli-Richard et al. 2007; Graham et al. 2006 ]. Thus, there are a number of reports of the induction or exacerbation of systemic lupus erythematosus (SLE) in patients treated with recombinant IFNa Nordmark et al. 2009; Yilmaz and Cimen, 2009] . Patients with risk factors (such as particular major histocompatibility complex (MHC) haplotypes, female gender, and others) that predispose an individual to the development of autoimmune disease, are particularly susceptible to the development of IFN-induced SLE, the symptoms of which usually resolve after discontinuation of IFN therapy Nordmark et al. 2009; Yilmaz et al. 2009 ]. Although the mechanism of IFN-induced SLE remains unclear, IFNa can be detected in the peripheral circulation of untreated SLE patients and a number of studies have shown an association between activation of the type I IFN pathway and disease activity [Ronnblom et al. 2006; Baechler et al. 2003 ]. Thus, the expression of a number of IFNinduced genes, a so-called IFN signature, is up regulated in peripheral blood mononuclear cells from SLE patients with active disease [Ronnblom et al. 2006; Baechler et al. 2003 ]. Furthermore, polymorphisms in the genes encoding IRF-5, [Burdick et al. 2009; Fabris et al. 2003; Levesque et al. 1999; Alsalameh et al. 1998 ], type I diabetes [Burdick et al. 2009; Fabris et al. 2003] , and autoimmune hepatitis [Duchini, 2002; Heathcote, 1995] . Thyroid dysfunction is also a relatively common side effect of IFN treatment, particularly in patients with pre-existing thyroid autoimmunity [Monzani et al. 2004] . As in the case of SLE, polymorphisms in the genes encoding proteins involved in the activation or activity of type I IFNs are also associated with a predisposition to develop certain of these diseases. For example, polymorphisms in the STAT4 and IRF5 genes are associated with an increased risk of developing systemic sclerosis, an autoimmune connective tissue disorder characterized by fibrosis of multiple organs and a type I IFN signature [Dieude et al. 2009; Ito et al. 2009; Rueda et al. 2009 ].
Treatment of patients with native or pegylated
IFNa is associated with a number of neuropsychiatric side effects including fatigue, depression, cognitive disturbances and, in some cases, suicidal tendencies [Dafny and Yang, 2005; Valentine et al. 1998 ]. A number of mechanisms have been implicated in these effects including effects of IFNs on neurons, serotonergic activity, neuro-endocrine cytokine secretion, tryptophan metabolism, and neurotransmitters [Dafny and Yang, 2005; Valentine et al. 1998 ]. The results of recent clinical trials in patients with MS suggest that depression is a less common adverse effect of IFNb therapy than was once thought and that flu-like symptoms and injection site reactions, particularly when IFNb is administered by the subcutaneous route, are among the most persistent side effects leading to cessation of treatment in some patients [Farrell and Giovannoni, 2010] .
Systemic administration of type I IFN results in the binding of IFN to receptors present on essentially all types of nucleated cells, including neurons and hematopoietic stem cells, in addition to target cells or target organ(s) involved in a particular disease. This may well explain the wide spectrum of adverse events associated with IFN therapy.
IL-2 IL-2 was approved in the USA in 1992 for the treatment of metastatic renal cell carcinoma and subsequently for the treatment of metastatic melanoma. Although IL-2 is effective in the treatment of metastatic renal cell carcinoma and metastatic melanoma, and can lead to complete remission in a small subset of patients [Antony and Dudek, 2010] , its widespread application has been limited by a spectrum of life-threatening side effects including hypotension, renal dysfunction, peripheral and pulmonary edema, and vascular leakage syndrome [Antony and Dudek, 2010] . IL-2-related toxicity is, however, generally reversible and only rarely causes permanent organ failure [Antony and Dudek, 2010] .
EPO
After over two decades of use in the treatment of chronic anemia in patients with chronic renal disease and in patients with cancer, recombinant EPO is considered to be safe and well tolerated. In spite of the improved erythropoiesis and reduced need for transfusions in cancer patients receiving recombinant EPO or its analogue, darbepoetin-alpha, meta-analysis has identified an increased risk of thrombo-embolic events during chemotherapy in patients receiving EPO, without increased on-study mortality or reduced overall survival [Dicato and Plawny, 2010] . Furthermore, patients with tumor cells that express EPO or EPO receptors have an unfavorable prognosis, raising concerns about tumor progression and the safety of erythropoiesis-stimulating agents [Dicato and Plawny, 2010] .
Rituximab
Rituximab (Rituxan Õ ) is a humanized monoclonal antibody that targets the B-cell differentiation antigen CD20. Rituximab is used extensively to treat non-Hodgkin's lymphoma and other B-cell lymphomas, as well as inflammatory diseases such as RA [Keating, 2010; Tak et al. 2010 ]. The action of rituximab is thought to be due at least in part to the depletion of CD20-bearing B cells [Weiner, 2010] , through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Rituximab is in general well tolerated although treatment is associated with infusion reactions, which in some cases may be fatal, tumor lysis syndrome, and some cases of acute renal failure [Kunkel et al. 2000 ]. Rituximab treatment is also associated with serious infections, including sepsis [Furst, 2010; Kunkel et al. 2000] , and some cases of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease caused by reactivation of the polyoma virus JC virus in immunosuppressed individuals [Berger, 2010] .
TNF antagonists
Several types of TNFa antagonists, including a chimeric antibody (infliximab), a human antibody (adalimumab), a pegylated F(ab') fragment (certolizumab), and etanercept, a fusion protein composed of the p75-soluble TNF receptor and the Fc fragment of IgG1, are currently used for the treatment of RA, a debilitating disease characterized by persistent synovitis, systemic inflammation, and the presence of auto-antibodies [Nam et al. 2010 ]. The anti-TNFa monoclonal antibodies infliximab, adalimumab, and certolizumab are also used to treat inflammatory bowel diseases, including Crohn's disease [Peyrin-Biroulet, 2010] . Although TNFa antagonists are, for the most part, well tolerated, their use is associated with an increased risk of granulomatous infections, particularly the reactivation of tuberculosis [Dixon et al. 2010 ]. The incidence of infection is higher in patients treated with infliximab and adalimumab than in patients treated with etanercept [Dixon et al. 2010] . There are also a number of reports of reactivation Therapeutic Advances in Drug Safety 2 (3) of latent virus infections including hepatitis B virus (HBV) [Carroll and Forgione, 2010] . Treatment of patients with TNFa antagonists is also associated with induction of inflammatory and autoimmune diseases, such as SLE [Costa et al. 2008] , and psoriasis [Cohen et al. 2007 ]. The results of a recent meta-analysis reveal an increased incidence in malignancies in patients treated with TNFa antagonists [Bongartz et al. 2006 ]. Thus, a statistically significant increase in the incidence of solid tumors was observed in patients with Wegener granulomatosis treated with etanercept [Stone, 2005] , and nonmelanoma skin cancers in patients with RA treated with TNFa antagonists [Chakravarty et al. 2005] . Lymphomas and nonhematological malignancies did not appear to occur with an increased frequency, however, when compared with population-based incidence data [Bongartz et al. 2006 ]. There are reports of the development of demyelinating disease in patients with inflammatory disease treated with TNFa antagonists [Alshekhlee et al. 2010; Bernatsky et al. 2010] . TNFa is associated, however, with both the development of MS in man [Sharief and Hentges, 1991] , and experimental autoimmune encephalomyelitis (EAE) in animals. TNFa antagonists have also been shown to decrease the severity of EAE in rodents [Selmaj and Raine, 1995] . A systematic review of the literature and the BIOBADASER pharmacovigilance database has shown that the number of cases of demyelinating disease in patients treated with TNFa antagonists does not differ from the background population suggesting that demyelination may not reflect a true association with the treatment regimen [Fernandez-Espartero et al. 2011 ]. The authors suggest, however, that the use of TNFa antagonists in patients with both a rheumatic and a demyelinating disease is counter indicated [Fernandez-Espartero et al. 2011] .
Natalizumab Natalizumab (Tysabri Õ ) is a humanized monoclonal antibody that targets a4-integrins preventing leukocytes adhering to endothelial vascular cell adhesion molecule-1, and hence reducing trafficking across the blood brain barrier [Coyle, 2010] . Natalizumab has been shown to be effective for the treatment of RRMS [Coyle, 2010] . It is approved for the therapy of RRMS based on its efficacy in the SENTINEL trial in combination with IFNb-1a and its efficacy as monotherapy in the AFFIRM trial [Coyle, 2010; Rudick and Panzara, 2008] . Natalizumab monotherapy has been shown to reduce the risk of disability progression by 4254%, the annualized relapse rate by 68%, and to reduce significantly central nervous system (CNS) lesions detected by magnetic resonance imaging (MRI) [Coyle, 2010; Rudick et al. 2008] . Although natalizumab is for the most part well tolerated, side effects include anaphylactic reactions (<1.0% of patients) and other hypersensitivity reactions, increased risk of infection, depression, and rash. A number of cases of PML have also been reported in natalizumabtreated patients, particularly those treated for 2 years or more [Clifford et al. 2010] , necessitating particular vigilance in regard to its safety profile. Approximately 10% of patients develop neutralizing antibodies to natalizumab, which persist for 12 months or more in 6% of patients [Calabresi et al. 2007 ]. There are a number of case reports of melanoma in patients treated with natalizumab with no previous history of melanoma, and in patients with pre-existing nevi that developed into melanoma [Laroni et al. 2011; Prinz Vavricka et al. 2010; Bergamaschi and Montomoli, 2009; Ismail et al. 2009 ]. Although it has been suggested that the target of natalizumab, a(4)b1 integrin, may play a role in the invasiveness of melanoma [Castela et al. 2011] , it remains to be shown whether the incidence of melanoma is increased in natalizumabtreated patients relative to the background population.
Results from the AFFIRM and SENTINEL trials show that some 9% of patients with MS develop antibodies to natalizumab of which some 6% were persistent and, for the most part, neutralizing [Calabresi et al. 2007 ]. The presence of persistent antibodies was associated with reduced clinical efficacy and infusionrelated adverse events including hypersensitivity reactions [Calabresi et al. 2007 ]. Most of those patients who develop an ADA response did so within 12 weeks (88% in the AFFIRM trial). A small group of patients (3%) developed a transient ADA response that lead to a delay in the clinical response to natalizumab therapy, although clinical efficacy was restored once antinatalizumab antibodies were no longer detectable after 6 months of continued treatment [Calabresi et al. 2007 ]. The authors recommended that patients with disease activity or persistent infusion reaction after 6 months of natalizumab therapy should be tested for ADAs. Obviously therapy should be discontinued in patients who develop hypersensitivity reactions.
Daclizumab
Daclizumab is a humanized monoclonal antibody that targets the high affinity IL-2 receptor, CD25, which is up regulated upon T-cell activation. Daclizumab has been used extensively for the prevention of allograft rejection [Campara et al. 2010] , and more recently for the treatment of RRMS [Wynn et al. 2010] . Daclizumab is thought to act at least in part by expansion of a regulatory subset of CD56 bright NK cells that kill activated T cells present in inflammatory lesions [Bielekova et al. 2006; Campara et al. 2010] . Daclizumab is for the most part well tolerated with a relatively low incidence of infections and other adverse events including mild hypersensitivity reactions observed in renal transplant patients [Campara et al. 2010] . Increased mortality has been observed, however, in cardiac transplant recipients treated with daclizumab together with standard immunosuppressive therapy [Hershberger et al. 2005] .
Alemtuzumab
Alemtuzumab (Campath-1H Õ and Campath Õ ) is a humanized monoclonal antibody that targets CD52, a leukocyte-differentiation antigen, present on most leukocytes including B cells, T cells, NK cells, and monocytes/macrophages [Bates, 2009] . Alemtuzumab is used for the treatment of various neoplastic diseases including chronic lymphocytic leukemia [Schweighofer and Wendtner, 2010] , and more recently for the treatment of RRMS [Coles et al. 2008 ]. Alemtuzumab treatment depletes B cells and T cells for extended periods and its use is associated with significant side effects, including frequent infusion reactions such as pyrexia, malaise, and rash, and an increased rate of infections [Minagar et al. 2010; Coles et al. 2008] . Alemtuzumab treatment is also associated with the development of autoimmunity including thyroid disorders, predominately Grave's disease, in approximately 30% of patients with MS but intriguingly not in patients with cancer [Minagar et al. 2010 ]. Among the most serious adverse event observed in MS patients treated with alemtuzumab are Goodpasture's syndrome reported in three patients [Farrell and Giovannoni, 2010] , and immune thrombocytopenic purpura (ITP). Six cases of ITP, including one fatal case, were reported in one clinical trial [Coles et al. 2008] .
Adverse events: underlying mechanisms and clinical implications
It is clear from a consideration of different types of biopharmaceuticals ranging from recombinant analogues of authentic human growth factors such as EPO, or cytokines such as type I IFNs or IL-2 to chimeric or human monoclonal antibodies that a pattern of some common side effects does emerge. Thus, administration of a number of these biopharmaceuticals is associated with infusion reactions, increased rates of infection, activation of latent viruses, and induction or reactivation of autoimmune disease. Given the key role played by type I IFNs in the innate immune response it is perhaps not surprising that dysregulation of the type I IFN pathway can under certain circumstances lead to induction or exacerbation of autoimmune disease in predisposed individuals [Burdick et al. 2009 ]. Thus, polymorphisms in the genes encoding key intermediates in the type I IFN pathway have been identified as risk factors for the development of autoimmune disease [Dieude et al. 2009; Ito et al. 2009; Rueda et al. 2009] , and a number of IFN-induced proteins are up regulated in active disease [Ronnblom et al. 2006; Baechler et al. 2003 ]. Furthermore, a recent report has shown that a loss of function variant in the gene encoding MAVS, a key antiviral molecule downstream of the cytosolic doublestranded RNA sensors RIG-I and MDA-5, is associated with low type I IFN production and the absence of anti-RNA-binding protein autoantibodies in a novel subphenotype of SLE [Pothlichet et al. 2011] .
It may appear paradoxical that antagonists of the pro-inflammatory cytokine TNFa that are used widely for the treatment of inflammatory and autoimmune diseases can induce SLE [Costa et al. 2008 ], or psoriasis [Ko et al. 2009; Cohen et al. 2007 ], in some individuals. Plasmacytoid dendritic cells (pDCs) that infiltrate the target organs of a number of autoimmune diseases, including SLE and psoriasis, secrete large amounts of IFNa, which is thought to play a role in the disease process [Burdick et al. 2009 ]. TNFa suppresses the generation of pDCs and the production of IFNa [Palucka et al. 2005] , which may explain at least in part the observed exacerbation of autoimmune disease in some individuals treated with TNFa antagonists. Reactivation of tuberculosis in patients treated with TNFa antagonists [Dixon et al. 2010] , reflects the important role played by TNFa in concert with IFNg in the adaptive immune response and the containment and eradication of Mycobacterium tuberculosis infection. Similarly, reactivation of HBV in patients treated with TNFa antagonists may be related to a reduced virus-specific CD8þ T-cell response in the presence of lower intrahepatic levels of TNFa. Thus, polymorphisms in the TNFa gene that lead to lower levels of TNFa production are related to an increased risk of progression to chronic HBV infection, while reduced levels of intrahepatic levels of TNFa lead to reduced expression of MHC class I antigens and a reduced virus-specific CD8þ T-cell response [Carroll and Forgione, 2010] .
It has been suggested, based on cumulative clinical experience that patients chronically infected with HBV who require therapy with a TNFa antagonist should be treated with antiviral therapy 12 weeks prior to treatment with a TNFa antagonist. In addition, baseline liver function, based on serum albumin and alanine transaminase levels and HBV DNA viral load, should be determined at the start of antiviral therapy and antiTNFa therapy and every 12 months thereafter [Carroll and Forgione, 2010] .
The detection of some 85 cases of PML in patients with RRMS treated with natalizumab as of January 2011 [Gryta, 2011] , equivalent to an incidence of approximately 1 case per 1000, necessitates particular vigilance especially in patients treated for 2 years or more [Ryschkewitsch et al. 2010 ]. Furthermore, the observation that JC virus DNA can persist in the cerebrospinal fluid (CSF) for years, even in the presence of high levels of anti-JC virus antibody, may warrant periodic testing for the presence of viral DNA in the CSF as well as in serum [Ryschkewitsch et al. 2010] . Three cases of PML were also reported in patients with psoriasis treated with the monoclonal antibody, efalizumab [Lysandropoulos and Du Pasquier, 2010] , which targets the integrin, LFA-1 (CD11a). Cases of PML have also been detected in RA patients treated with the antiCD20 antibody, rituximab [Berger, 2010; Paues and Vrethem, 2010; Bongartz et al. 2006 ], suggesting a possible causal association between the increased number of pre-B cells, some of which contain JC virus, detected in the circulation of patients treated with either rituximab or natalizumab [Allison, 2010] . As of March 2009, some 57 cases of PML in rituximab-treated patients have been reported [Carson et al. 2009] , with some additional cases reported since that time [Lysandropoulos and Du Pasquier, 2010; Paues and Vrethem, 2010] . Thus, vigilance is again called for when treating patients with RA or non-Hodgkin's lymphoma with rituximab.
The dose-dependent increase in the risk of malignancies in RA patients treated with high doses of TNFa antagonists suggests that the marginal if any gain in efficacy should be weighed against the increase risk on an individual basis [Bongartz et al. 2006 ]. The absence of an accumulation of malignancies with longer study duration is suggestive of a potentiation of pre-existing malignancies rather than induction suggesting that systematic screening for pre-existing malignancies and subsequent surveillance may provide a means of improving the safety of antiTNFa therapy [Bongartz et al. 2006 ].
Immunogenicity of biopharmaceuticals
It is well established that repeated injection of even native human proteins can result in a break in immune tolerance to self-antigens in some patients leading to a humoral response against the protein that is enhanced when the protein is aggregated or partially denatured [Van Beers et al. 2010] . Although in most cases an immune response to a biopharmaceutical has little or no clinical impact, ADAs do, however, pose a number of potential risks for the patient, particularly in the case of a neutralizing antibody response. Firstly, an ADA response can adversely affect the pharmacokinetics and bioavailability of a drug thereby reducing the efficacy of treatment and necessitating either dose escalation or switching to alternative therapy if such therapy is available. An ADA response can also adversely affect the safety of treatment and cause immune complex disease, allergic reactions and, in some cases, severe autoimmune reactions. Serious and lifethreatening adverse events can occur when ADAs cross react with an essential nonredundant endogenous protein such as EPO or thrombopoietin [Casadevall et al. 2002; Li et al. 2001 ]. Thus, several cases of pure red cell aplasia were associated with the development of antibodies to recombinant EPO following a change in formulation [Casadevall et al. 2002] . Similarly, the development of antibodies to pegylated megakaryocyte growth and development factor (MGDF) cross reacted with endogenous MGDF resulting in several cases of severe thrombocytopenia [Li et al. 2001 ].
Factors influencing the immunogenicity of biopharmaceuticals
Currently available techniques do not permit one to predict with a sufficient degree of accuracy whether a biopharmaceutical will be immunogenic and if so, to what extent. It is also difficult to predict which patients will develop an immune response to a particular drug, and at what time during treatment an immune response will occur. There are, however, a number of both drugrelated and patient-related factors that are known to influence the immunogenicity of biopharmaceuticals (Figure 1) . Drug-related factors include the presence of nonhuman sequences or novel epitopes generated by amino acid substitution designed to enhance stability, or novel epitopes created at the junction of fusion proteins. Molecular structure, and in particular, changes in glycosylation, can also influence the immunogenicity of a biopharmaceutical. Thus, the absence of glycosylation or an altered pattern of glycosylation can expose cryptic B-cell and T-cell epitopes in the protein, or cause the protein to appear foreign to the immune system. Carbohydrate moieties present upon biopharmaceuticals can elicit the production of IgE antibodies that can cause serious adverse reactions including anaphylaxis even upon the first treatment exposure. Pre-existing antibodies against galactose-a-1,3-galactose have been shown to be responsible for IgE-mediated anaphylactic reactions in patients treated with cetuximab [Chung et al. 2008] . Pegylation can reduce the immunogenicity of some proteins although patients produce antibodies to the PEG residue adversely affecting efficacy [Armstrong et al. 2007 ]. In addition to attributes that can induce a classical immune response, repeated administration of even authentic human proteins such as albumin can under certain circumstances cause a break in Therapeutic Advances in Drug Safety 2 (3) immune tolerance leading to the development of an immune response. Thus, the presence of degradation products resulting from oxidation or deamination of the protein, aggregates, or the intrinsic immunomodulatory properties of the molecule can also influence the immunogenicity of a biopharmaceutical. Protein aggregation in particular has long been associated with increased immunogenicity [Moore and Leppert, 1980] , although the mechanisms underlying this effect remain poorly understood. It has been suggested that aggregated proteins form repetitive arrays that can lead to efficient cross-linking of B-cell receptors, leading to B-cell activation in the absence of T-cell help, thereby resulting in a break in immune tolerance to self-proteins [Felipe et al. 2010] .
The relatively high incidence of ADAs in patients treated with recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) may be related at least in part to the immunostimulatory properties of the molecule itself [Rini et al. 2005 ]. Thus, GM-CSF can recruit antigen-presenting cells to the site of antigen processing, stimulate the maturation of myeloid DCs, and enhance an antigen-specific CD8þ T-cell response, suggesting that repeated administration of GM-CSF may function as an adjuvant. Indeed, GM-CSF has been used as an immunological adjuvant in a number of vaccination protocols designed to elicit an immune response to self-antigens [Parmiani et al. 2007 ].
Process-related impurities, including traces of residual DNA or proteins from the expression system, or contaminants that leach from the product container, can also influence the immunogenicity of recombinant biopharmaceuticals [Wadhwa et al. 1999 ].
Patient-related factors, such as genetic makeup, age, gender, disease status, concomitant medication, and route of administration, can also influence the immune response to a particular biopharmaceutical. For example, a common MHC class II allele, DRB1*0701, is associated with the antibody response to IFNb in MS patients [Barbosa et al. 2006 ]. Disease state and immune competency also influence the immune response of an individual to a treatment with a biopharmaceutical. Thus, development of antibodies to pegylated MGDF is less frequent in cancer patients who tend to be immunosuppressed than in healthy individuals [Li et al. 2001 ]. Concomitant therapy with immunosuppressive drugs can also influence a patient's immune response to a biopharmaceutical. Thus, administration of methotrexate together with the chimeric monoclonal antibody infliximab has been shown to reduce the immune response to infliximab and improve the clinical response in patients with RA [Maini et al. 1998 ]. The duration of treatment and the route of administration also influence the immune response to a biopharmaceutical. Typically, administration of a protein in a single dose results in the production of low-affinity IgM antibodies, while repeated administration results in the production of high-affinity and high-titer IgG antibodies, which may be neutralizing. Thus, in patients with MS treated with IFNb neutralizing antibodies to IFNb often do not appear until after several months of therapy [Giovannoni, 2003] . The intravenous route of administration is considered to be least likely to generate an immune response to a biopharmaceutical compared with intramuscular or subcutaneous administration.
The complexity of the humoral response to biopharmaceuticals and the difficulty in establishing the effect on ADAs on drug efficacy is illustrated by the response of patients to treatment with IFNb, first licensed over a decade ago for the treatment of RRMS. Five products are currently available in the USA and Europe as first-line disease-modifying agents for the treatment of RRMS, IFNb-1a (Avonex Õ and Rebif Õ ), IFNb-1b (Betaseron Õ and Betaferon Õ ), and more recently, the IFNb-1b biosimilar Extavia Õ . Avonex Õ and Rebif Õ are both glycosylated forms of native human IFNb-1a produced in Chinese hamster ovary cells. Betaseron Õ and Extavia Õ are a nonglycosylated form of IFNb-1a produced in Escherichia coli that has a serine substitution for the unpaired cystine at position 17 of the native protein. These drugs are partially effective; they reduce the number of relapses by about one third, reduce the number of CNS lesions detected by MRI by approximately 70%, and may also delay disease progression. Most patients develop an antibody response to IFNb products, and as many as up to 45% of patients develop neutralizing antibodies to IFNb, in some cases as early as 3 months after initiation of therapy. Overall, some 25% of patients develop antiIFNb-neutralizing antibodies usually within 618 months. ADAs are more frequent in patients treated with IFNb-1b than IFNb-1a, while subcutaneous IFNb-1a (Rebif Õ ) is more immunogenic than intramuscular IFNb-1a (Avonex Õ ) [Malucchi et al. 2004] . The immunogenicity of IFNb varies among individuals, both as a function of the presence of particular MHC class II alleles, and as a function of IFN-receptor expression. Thus, patients who process the DRB1*0701 allele, or who express low levels of IFNAR2, one of the two chains of the type I IFN receptor, upon initiation of treatment, have a significantly higher risk of developing antiIFNbneutralizing antibodies [Farrell and Giovannoni, 2010] .
Although it has been shown in numerous trials that patients who develop antibodies against IFNb have higher relapse rates, increased number of lesions detected by MRI, and higher rates of disease progression [Francis et al. 2005; Kappos et al. 2005] , the significance of antiIFNb ADAs remains controversial [Goodin et al. 2007 ]. This is due to the difficulty in establishing a temporal correlation between the presence of antiIFNb ADAs and the loss of drug efficacy due to the variable nature of the disease, the partial effectiveness of the drug, the delay between initiation of treatment and the detection of an effect of the drug on the course of the disease, and the difference in the immunogenicity of different IFNb products. The lack of standardized ADA assays has also rendered direct comparisons of immunogenicity between different products and different studies difficult, which has contributed to the difficulty in establishing a correlation between ADAs and loss of drug efficacy. The development of a standardized cell-based assay for the quantification of antidrug-neutralizing antibodies that allows direct comparisons between different IFNb products [Lallemand et al. 2010 [Lallemand et al. , 2008 is discussed in the following. Although differences in approach and emphasis exist between the USA, European Union, and Japanese regulatory authorities there is, nevertheless, a large degree of consensus on the type of approach that should be adopted; namely, a risk-based approach that is clinically driven and takes into account pharmacokinetic data. Thus, biopharmaceuticals with no endogenous counterpart are considered to be of relative low risk while drugs with a nonredundant endogenous counterpart are considered to present a high risk. A multi-tiered approach to testing samples is also recommended. This consists of an appropriate screening assay capable of detecting both IgM and IgG ADAs, the sensitivity of which is such that a percentage of false-positive samples would be detected. The specificity of the samples that test positive in the screening assay are then re-assayed in a confirmatory assay usually by competition with an unlabelled drug using the same assay format as that used for the screening assay. Samples that test positive in the screening and confirmatory assays are then tested for the presence of neutralizing ADAs using a cell-based assay whenever possible. Although it may be appropriate to use ligand-binding assays for certain monoclonal antibodies that target soluble antigens, some ADAs may not be detected using a ligand-binding assay. Thus, antibodies have been described that inhibit the antiviral activity of type I IFNs by inducing hyperphosphorylation of a receptor-associated tyrosine kinase without inhibiting binding of IFN to its receptor [Novick et al. 2000 ].
Regulatory guidance
Cell-based assays for the quantification of neutralizing antidrug antibodies Although regulatory authorities recommend the use of cell-based assays for the detection and quantification of neutralizing antibodies, cellbased assays often give variable results and are notoriously difficult to standardize.
Conventional cell-based assays for neutralizing antibodies are based upon the assessment of a drug-induced response in a drug-sensitive cell line, and the ability of an antibody to inhibit that response. The form of the assay can vary considerably, however, reflecting the diversity of the biopharmaceuticals currently employed in the clinic. Drug-induced responses vary from stimulation of cell proliferation in the presence of a growth factor such as EPO or GM-CSF, or induction of apoptosis in the presence of TNFa to inhibition of virus replication in IFNtreated cells [Meager, 2006] . Such drug-induced responses are complex events involving the transcriptional activation or modulation of numerous genes. Drug-induced biological responses also often take several days to develop and are influenced by a number of factors that are difficult to control.
A series of engineered reporter cell lines have been developed for the quantification of the activity and neutralizing antibody response to biopharmaceuticals that eliminate many of the limitations of conventional cell-based assays.
In order to improve the performance of conventional cell-based assays and to develop assays that allow more direct comparisons of immunogenicity data, reporter cell lines were established based on transfection of cells with the firefly luciferase reporter gene regulated by a drug-responsive chimeric promoter [Lallemand et al. 2008 ]. These assays allow drug activity, and the neutralization of drug activity, to be determined selectively and with a high degree of precision within a few hours by measuring light emission [Lallemand et al. 2008 ]. In addition, the use of a single common drug-induced response for a variety of different drugs facilitates comparisons of immunogenicity data.
Conventional cell-based assays are difficult to standardize due in part to assay variation resulting from changes in culture conditions and genetic and epigenetic changes that can occur as cells are cultivated continuously in the laboratory. Assay variation can be minimized by the use of cell banks and preparation of each lot of assay cells under standardized conditions from an individual frozen vial [Lallemand et al. 2008] . Each lot of assay cells is thus in an identical physiological condition. Assay-ready cells can be manufactured under conditions of current good manufacturing practices, and stored frozen for several years without loss of drug sensitivity [Lallemand et al. 2008] .
In order to render cell-based assays less labor intensive and more amenable to automation, an assay was developed that allows the level of drug activity and antidrug-neutralizing antibodies to be determined in a serum sample simply by the addition of reporter cells without further dilution, or the addition of exogenous drug [Lallemand et al. 2010] . The so called one-step assay is based on a cell line that has been engineered to express and secrete the biopharmaceutical of interest together with a reporter-gene transcribed from the same inducible promoter. Expression of the drug is thus strictly proportional to expression of the reporter gene, thereby allowing drug production to be quantified with precision. The cells also contain a second reporter gene [Grossberg et al. 2009 ], controlled by a drugresponsive chimeric promoter that allows drug activity to be quantified.
The presence of antidrug-neutralizing antibodies in a sample will neutralize a quantity of drug secreted from the reporter cell, proportional to the neutralizing capacity of the antibody. This will prevent the drug from binding to its specific cell-surface receptor, thereby resulting in a corresponding reduction in the expression of the drug-responsive reporter gene. Expression of the drug-responsive reporter gene in the presence or absence of the ADA-containing sample will allow the relative neutralizing titer of the sample to be quantified by the constant antibody method, as a function of the quantity of drug required to neutralize a sample, determined from the level of expression the reporter gene transcribed from the same promoter as the drug [Lallemand et al. 2010] . Results are normalized relative to the expression of an internal standard, and are consequently independent of cell number, thus affording a high degree of assay precision and reducing serum matrix effects to a minimum. The one-step assay is applicable to a wide range of biopharmaceuticals and is ideally suited to high throughput analysis of antidrugneutralizing antibodies during clinical development or routine patient monitoring.
Conclusion
Biopharmaceuticals are widely used for the treatment of numerous indications including many serious debilitating and life-threatening diseases. Biopharmaceuticals are for the most part well tolerated and represent an important addition to the modern drug armamentarium. The use of some biopharmaceuticals is limited, however, by serious adverse events that occur in some individuals. A number of these adverse events, including infusion reactions, increased rates of infection, activation of latent viruses, and induction or reactivation of autoimmune disease, are observed with different types of biopharmaceuticals. Undesired immunogenicity can also limit the use of biopharmaceuticals, particularly for the treatment of chronic diseases that necessitate repeated treatments over long periods. The development of improved assays, particularly cell-based assays for the detection of neutralizing antibodies, that allow immunogenicity to be determined with precision and the comparison of immunogenicity data between biopharmaceuticals, are critical for the development of less immunogenic and safer biopharmaceuticals.
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